<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cancer vaccine on FinanClub</title>
    <link>https://finan.club/tags/cancer-vaccine/</link>
    <description>Recent content in Cancer vaccine on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 25 Mar 2024 09:05:37 +0000</lastBuildDate><atom:link href="https://finan.club/tags/cancer-vaccine/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Mon, 25 Mar 2024 09:05:37 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:153
Chances: Recent publication of preclinical data in the online issue of Science, First Release indicating potential for managing HIV without antiretroviral treatment Phase 1 pilot study showing potential for reducing viral load in people living with HIV Completion of safety portions of clinical trial studying investigational cancer vaccine for participants with Lynch syndrome Risks: Need for further clinical trials to validate the potential of N-803 and natural killer cells for managing HIV Uncertainty around regulatory approval for commercialization efforts despite significant financial resources Score:153 chances characters count - risks characters count = 153</description>
    </item>
    
  </channel>
</rss>
